Advertisement

Topics

Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma

01:00 EDT 30 Jun 2017 | Hoffmann-La Roche Ltd

Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company’s investigational medicine polatuzumab vedotin in combination with MabThera® (rituximab) and bendamustine for the treatment of people with relapsed or refractory diffuse large B cell lymphoma (DLBCL), the most common aggressive form of non-Hodgkin lymphoma.

Original Article: Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma

NEXT ARTICLE

More From BioPortfolio on "Roche’s polatuzumab vedotin receives priority medicines scheme (PRIME) designation for treatment of the most common form of aggressive lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement